parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	5 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 13574

WASF3 in dopamine neurons, braak+0.37 (p 0.334) → +0.11 (p 0.785)receipt 13585
WASF3 in astrocytes, braak+0.03 (p 0.944) → -0.19 (p 0.631)receipt 13584

receipt 13585: WASF3 in dopamine neurons, braak

power: full sample +0.28 (p 0.261, n 18), 95% CI -0.22 to +0.66. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.24 (p 0.341, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.22 (p 0.379, n 18). could be the mix.
skeptic: leave-one-out range +0.20 to +0.37, sign flips 0; without severely affected donors +0.28 (p 0.261, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for WASF3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 13584: WASF3 in astrocytes, braak

power: full sample -0.28 (p 0.254, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.39 (p 0.111, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.36 (p 0.142, n 18). could be the mix.
skeptic: leave-one-out range -0.43 to -0.20, sign flips 0; without severely affected donors -0.28 (p 0.254, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for WASF3 in astrocytes.

case closed: nothing better to follow up.

loading the receipts